We're looking forward to attending the 13th annual Forbes Healthcare Summit. Our CEO and Founder, Eric Lefkofsky, will take the stage on December 4 at 10:20 AM EST to discuss bringing the power of data and AI to healthcare.
Tempus AI
Biotechnology Research
Chicago, IL 82,655 followers
Tempus is advancing data-driven precision medicine with the practical application of AI in healthcare. It’s About Time.
About us
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).
- Website
-
http://www.tempus.com
External link for Tempus AI
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Chicago, IL
- Type
- Privately Held
- Founded
- 2015
Locations
Employees at Tempus AI
Updates
-
Don't forget to register for this week's #webinar, "Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies" on Thursday, December 5 at 12 PM CT. Moderator Calvin Chao, MD will be speaking with Natalie Vokes, MD, Douglas Palmer, PhD, and Timothy J. Taxter, M.D. about the significant developments that are helping to shape clinical trials and enhance patient outcomes in #IO. Register here: https://tempus.co/4fTQs4v
-
-
In a recent Q&A, Dr. Michelle Ting-Lin, Medical Director of Clinical Development at Tempus, provides insights into the science behind the Immune Profile Score (IPS), a novel biomarker designed to enhance the identification of patients who may benefit from immune checkpoint inhibitor (ICI) therapies. Read here: https://tempus.co/4i9EftN
-
-
We're looking forward to participating in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, in New York. Our CEO and founder Eric Lefkofsky will participate in a fireside discussion on December 3 at 3:00 p.m. ET. Learn more: https://tempus.co/4eMkm9a
-
-
Join us for an upcoming webinar, “Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies” on December 5 at 12 PM CT. Hear from Calvin Chao, MD, Timothy J. Taxter, M.D., and Natalie Vokes, MD, on the role novel biomarkers and combination treatment strategies play in understanding and enhancing the immune system's response to cancer. Register here: https://tempus.co/4fxjfeS
-
-
A recent case study illustrates Tempus Next’s ability to help close the biomarker testing gap for early stage #NSCLC. Tempus Next was deployed to help TriHealth Cancer and Blood Institute achieve 100% compliance with targeted biomarker testing guidelines for resectable stage IB-III NSCLC. Read the full case study here: https://tempus.co/3OjwfsE
-
-
We’re thrilled to announce this collaboration with Medtronic, which utilizes the Tempus Next platform to identify causes of undertreatment of minority patient groups with severe aortic stenosis, moderate to severe and severe mitral regurgitation for recommended therapies. By harnessing the power of AI, Tempus Next identifies care gaps and equips clinicians with actionable insights at the point of care.
SVP and President, Structural Heart & Aortic at Medtronic ✦ Board Member ✦ Growth Acceleration ✦ MedTech Innovation ✦ DEI
Today, marks a milestone for Medtronic in our work to address health disparities and gaps in access to life-saving solutions. I’m thrilled to share the launch of the ALERT study (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform), a study that will lean on artificial intelligence to identify patients in need of structural heart disease care. This news is yet another example of our commitment to creating solutions that will reach minority and underrepresented communities, where barriers to accessing minimally invasive treatments like TAVR are more pronounced. At a time when patients who are Black, Hispanic, Asian, or part of other racial groups have disproportionate rates of TAVR treatment compared to Caucasian patients – this is more important than ever. We are proud of our collaboration with Tempus AI and thank the sites around the country for participating in this important study and their dedication to reach underserved patients with TAVR treatment. https://lnkd.in/eVhKykkC
-
We are now offering germline RNA analysis as part of our comprehensive genetic testing portfolio. +RNAinsight® (powered by Ambry Genetics) analyzes RNA to support the classification and detection of DNA variants, including those that may be missed by DNA-only assays. It is now available as an add-on test for xG (CancerNext®) and xG+. Learn more: https://tempus.co/3UYrrg0
-
-
Reminder to join us for this week's webinar, “Precision outcomes research: Shaping the future of oncology biopharma with real-world evidence” on November 21 at 12 PM CT. Moderator Emilie Scherrer will be speaking with Vadim Koshkin, MD, Mark Stewart, PhD, and Somnath Sarkar, MD, to explore how leveraging outcomes data drives innovation and improves patient outcomes across the continuum of care. Register here: https://tempus.co/3UBKEE7
-
-
Immunotherapy is transforming cancer care, but identifying the right patients for these treatments remains a challenge. We are leading the way in immuno-oncology with our Immune Profile Score (IPS), a first-of-its-kind biomarker utilizing DNA and RNA to prognosticate immune checkpoint inhibitor (ICI) response. By addressing the complexities of biomarker identification in research, IPS can help overcome these challenges in an effort to improve patient outcomes. IPS is just one of the many solutions available through Tempus IO, our comprehensive platform designed to support your research with comprehensive real-world data, a robust suite of IO biomarkers, and advanced analytical technology. Learn more: https://tempus.co/3Cv7QO8